Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

    Cancer Categories
    • Gastrointestinal (GI),Lung
    Karmanos Trial ID
    • 2023-035
    NCT ID
    • NCT05012618
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator
    • Image of Mohammed Najeeb Al Hallak , M.D., MS
      Mohammed Najeeb
      Al Hallak, M.D., MS
      Oncology - Medical View Profile

    Objective:

    Primary Objective

      The primary objectives for this study are:

      • Part A (LUNA18 monotherapy dose escalation cohorts), Part AA (LUNA18 monotherapy backfill cohorts) and Part D (LUNA18 combination dose finding cohorts):
        • To evaluate the safety and tolerability of LUNA18 when administered as a single agent (Part A, Part AA) and in combination with other anti-cancer drugs (Part D)
        • To determine the maximum tolerated dose (MTD) and the recommended dose (RD) when administered as a single agent (Part A) and in combination with other anti-cancer drugs (Part D)
        • To characterize the PK profile of LUNA18 in plasma when administered as a single agent (Part A, Part AA) and in combination with other anti-cancer drugs (Part D)
      • Part B (LUNA18 monotherapy biomarker cohorts):
        • To evaluate the safety and tolerability of LUNA18
        • To evaluate the inhibition of the phosphorylation level of extracellular signal-regulated kinase (ERK) protein (pERK) and other biomarkers as applicable in tumor tissues
        • To evaluate the preliminary anti-tumor activity of LUNA18
      • Part C (LUNA18 monotherapy expansion cohorts) and Part E (LUNA18 combination expansion cohorts):
        • To evaluate the safety and tolerability of LUNA18 when administered as a single agent (Part C) and in combination with other anti-cancer drugs (Part E)
        • To evaluate the preliminary anti-tumor activity of LUNA18 when administered as a single agent (Part C) and in combination with other anti-cancer drugs (Part E)

        Secondary Objectives

          The secondary objectives for this study are:

          • Part A (LUNA18 monotherapy dose escalation cohorts), Part AA (LUNA18 monotherapy backfill cohorts) and Part D (LUNA18 combination dose finding cohorts):
            • To evaluate the preliminary anti-tumor activity of LUNA18 when administered as a single agent (Part A, Part AA) and in combination with other anti-cancer drugs (Part D)
            • To evaluate the immunogenicity of LUNA18 when administered as a single agent (Part A, Part AA) and in combination with other anti-cancer drugs (Part D)
            • To evaluate the inhibition of the phosphorylation level of pERK and other biomarkers as applicable in tumor tissues when administered as a single agent (Part A, Part AA) and in combination with other anti-cancer drugs (Part D)
            • To evaluate the difference of LUNA18 PK between hard capsule and soft capsule (Part A, Part AA)
            • To evaluate the difference of LUNA18 PK between monotherapy (Part A, Part AA) and combination therapy (Part D)
            • To characterize PK profile and immunogenicity of other anti-cancer drugs when administered in combination with LUNA18 (Part D)
          • Part B (LUNA18 monotherapy biomarker cohorts):
            • To evaluate the additional preliminary anti-tumor activity of LUNA18
            • To characterize the PK profile and to evaluate the immunogenicity of LUNA18
          • Part C (LUNA18 monotherapy expansion cohorts) and Part E (LUNA18 combination expansion cohorts):
            • To evaluate the additional preliminary anti-tumor activity of LUNA18 when administered as a single agent (Part C) and in combination with other anti-cancer drugs (Part E)
            • To characterize PK profile and to evaluate the immunogenicity of LUNA18 when administered as a single agent (Part C) and in combination with other anti-cancer drugs (Part E)
            • To evaluate the inhibition of the phosphorylation level of pERK and other biomarkers as applicable in tumor tissues when administered as a single agent (Part C) and in combination with other anti-cancer drugs (Part E)
            • To characterize PK profile and immunogenicity of other anti-cancer drugs when administered in combination with LUNA18 (Part E)
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 1-800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 1-800-527-6266